Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
LIBOURNE, France and DURHAM, N.C., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use.
|
|||||||||
“KCS is a disease that causes much pain and discomfort, particularly in dogs. If left untreated, severe cases may lead to blindness,” said Jon Alšėnas DVM, President and CEO of Zoion Pharma. “Ceva is the ideal partner to bring this potentially very exciting new therapy to companion animals and their owners around the world.”
Financial terms of the collaboration were not disclosed.
About Ceva Santé Animale:
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne, France.
About Zoion Pharma:
Zoion Pharma is dedicated to the goal of identifying, sourcing and developing novel or overlooked drugs specifically for use in the treatment of companion animal diseases of high unmet medical need.
About Parion Sciences:
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the lung or eye. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and leverages its scientific expertise in epithelial biology to expand the company’s platforms and novel chemical compounds into new potential indications to treat mucosal defects.
CONTACT: Jon Alsenas [email protected]
